Withdrawal of Registration Statement (ammendment) (aw)
April 28 2022 - 4:29PM
Edgar (US Regulatory)
NeuroSense Therapeutics Ltd.
11 HaMenofim Street, Building B
Herzliya 4672562 Israel
April 28, 2022
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Dillon Hagius
| Re: | NeuroSense Therapeutics Ltd.—Request for Withdrawal
of Post-Effective Amendment
No. 1 to the Registration Statement on Form F-1 (File No. 333-260338) |
Dear Mr. Hagius:
Pursuant
to Rule 477 under the Securities Act of 1933, as amended, NeuroSense Therapeutics Ltd. (the “Company”) hereby requests the
withdrawal of Post-Effective Amendment No. 1 (Accession No. 0001213900-22-019892) to its registration statement
on Form F-1 (File No. 333-260338), together with all exhibits filed therewith, filed on April 15, 2022 (the
“Amendment”).
The
Amendment was inadvertently tagged as an “POS AM” which is the EDGAR submission type used to file a post-effective amendment
that is not immediately effective upon filing, instead of being tagged as a “POS EX” which is the EDGAR submission type used
to file a post-effective amendment that is immediately effective upon filing. The Company intends to promptly re-file the Amendment
as a “POS EX” with no changes other than the filing submission type.
The Amendment was not declared
effective, and no securities have been issued or sold in connection with the Amendment.
|
Sincerely, |
|
|
|
NeuroSense Therapeutics Ltd. |
|
|
|
|
By: |
/s/ Alon Ben-Noon |
|
|
Alon Ben-Noon |
|
|
Chief Executive Officer |
NeuroSense Therapeutics (NASDAQ:NRSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
NeuroSense Therapeutics (NASDAQ:NRSN)
Historical Stock Chart
From Apr 2023 to Apr 2024